Tempus, a leader in artificial intelligence and precision medicine, today announced five abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2023, which convenes in Madrid, Spain, from October 20-24, 2023. 

“We are excited to share our latest research at ESMO this year, as we continue to make our precision medicine offerings available for clinical applications in Europe,” said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. “This year’s abstracts demonstrate Tempus’ advanced genomic sequencing capabilities, which contribute to more informed, data-driven patient care in oncology.”

This year, Tempus will share a few of its latest scientific and clinical research findings via poster presentations, including: 

• Poster Presentation (182P): ALK Fusion Detection by RNA Next-Generation Sequencing (NGS) Compared to DNA in a Large, Real-World Non-Small Cell Lung Cancer (NSCLC) Dataset

• • Session Date & Time: Saturday, October 21, 2023; 12:00-13:00 CEST
  • Location: IFEMA MADRID; Hall 8
  • Overview: Researchers reviewed a cohort of 7,428 advanced-stage NSCLC patients from Tempus’ multimodal real-world database, and found a subset of patients with ALK fusions identified by at least one NGS assay (either EML4, KIF5B, KLC1, or PICALM as the fusion partner). Among those patients harboring ALK fusions the majority had the fusion detected by both DNA- and RNA-NGS, while some fusions were detected only by RNA-NGS, and a lower proportion were detected only by DNA-NGS. In total, combining both DNA- and RNA-NGS sequencing improved the detection of ALK fusions compared to DNA-NGS alone.

• Poster Presentation (185P): Real-world data analysis of genomic profiling-matched targeted therapy outcomes in patients with advanced fusion-positive NSCLC

• • Session Date & Time: Saturday, October 21, 2023; 12:00-13:00 CEST
  • Location: IFEMA MADRID; Hall 8
  • Overview: In a study of 1,950 advanced NSCLC patients, the research team leveraged Tempus’ multimodal real-world database to find that the majority of clinicians utilized comprehensive genomic profiling in a timely manner to treat patients with ESMO-recommended targeted therapy in fusion-positive cases (n=65). More importantly, patients having taken fusion-positive-matched guideline-recommended treatments had improved real-world overall survival compared to patients who did not receive the fusion-positive-matched therapy.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.